TNR Biopharm's cumulative revenue reaches ₩27.2B in the third quarter
Predicted impact: Low
Cumulative Q3 revenue of ₩27.2B is about 83% of last year's; preliminary earnings already filed.
246710 · KOSDAQ · ₩246710 · 티앤알바이오팹
Predicted impact: Low
Cumulative Q3 revenue of ₩27.2B is about 83% of last year's; preliminary earnings already filed.
Also known as: T&R Biofab / 티앤알바이오팹 / 246710 / KRX:246710
Source: KRX statistical information